Tara L. Lin

Tara L. Lin

Oncology

4350 Shawnee Mission Parkway
Fairway, KS 66205

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 109 publications

FLAG-Ida-venetoclax in acute myeloid leukemia: real-world efficacy and the impact of venetoclax duration on outcomes.

FLAG-Ida-venetoclax in acute myeloid leukemia: real-world efficacy and the impact of venetoclax duration on outcomes.

Journal: Leukemia & lymphoma

Published: July 15, 2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 02, 2026

Correction: CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis.

Correction: CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis.

Journal: Cardio-oncology (London, England)

Published: May 23, 2026

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

Journal: Blood

Published: May 04, 2026

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

Journal: American journal of hematology

Published: April 02, 2026

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

Journal: Blood

Published: March 18, 2026

Does age matter? Optimizing AML treatment in older adults.

Does age matter? Optimizing AML treatment in older adults.

Journal: Blood advances

Published: March 13, 2026

CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.

CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.

Journal: Blood advances

Published: December 11, 2025

CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.

CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.

Journal: Blood advances

Published: December 11, 2025

Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML Report.

Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML Report.

Journal: Blood advances

Published: November 19, 2025

Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.

Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.

Journal: Blood advances

Published: November 19, 2025

Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.

Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.

Journal: British journal of haematology

Published: September 11, 2025

Showing 1-12 of 109

Last Updated: 09/26/2026